Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05796232
Other study ID # RC 16/19
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 26, 2020
Est. completion date May 15, 2024

Study information

Verified date March 2023
Source IRCCS Burlo Garofolo
Contact Egidio Barbi, MD
Phone +390403785251
Email egidio.barbi@burlo.trieste.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The need to treat the children with painful diagnostic-therapeutic procedures has increased in the last years. There is evidence from a wide scientific literature that drugs available in the setting of procedural sedation and analgesia such as midazolam, fentanyl, nitrous oxide, ketamine and propofol are absolutely safe without a significant incidence of adverse effects, if administered by anaesthesiologists and also trained pediatricians outside the operating room. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that blocks glutamate excitatory effects. Ketamine's molecular mechanism is not restricted to the NMDA receptor. Several studies indicate interactions with a series of receptor systems, including opioid, cholinergic and dopaminergic receptors. Ketamine is a safe and effective drug during procedural analgesia and sedation applied to children outside the operating room. A recent multicenter study, showed that ketamine, without being associated with other analgesic or sedative drugs, is the drug regimen with the lowest risk of adverse effects during this procedures. Even though being safe, ketamine may cause some adverse effects. When ketamine is administered for procedural sedation outside the operating room, adverse effects more frequently recorded are emesis and recovery agitation, each with a prevalence of around 8%. Recovery agitation, defined as any abnormal behavioural response such as any combination of agitation, crying, hallucinations or nightmares after sedation, in some cases (around 1%) may be severe and leads to specific treatment, mainly benzodiazepines. Emesis and recovery agitation are minor adverse events, but both may be very unpleasant for the patient and may play a role in the perception of patients and their parents of the quality of sedation, especially in children who need repeated procedures. Identifying patients, particularly children with chronic illnesses and leukemia, at risk of emesis and recovery agitation may facilitate the choice of different drugs regimens, improving the quality of care. The aim of this study is the identification of genetic and epigenetic biomarkers useful to predict emesis and recovery agitation related to administration of ketamine for procedural sedation and analgesia applied to children and to correlate them with the pharmacokinetic profile.


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date May 15, 2024
Est. primary completion date May 15, 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria: 1. Any child between 1 and 17 years of age needing sedation and analgesia for painful procedures, such as suture laceration, fracture reductions, burn medications, bone marrow aspiration, lumbar puncture, arthrocentesis, colonoscopy and others. 2. Use of intravenous ketamine as the sole sedative agent for the procedure. Exclusion Criteria: 1. Children needing drugs other that ketamine for sedation, such as fentanyl, propofol, midazolam and dexmedetomidine . 2. Children with intellectual disability or with non typical neurodevelopment, such as children with autism. 3. Children with a history of allergy or hypersensibility to ketamine. 4. Parents limitations in language and understanding informed consent forms and procedures.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy IRCCS Burlo Garofolo Trieste

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Burlo Garofolo

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary To identify genetic variants associated with the development of emesis and recovery agitation after intravenous administration of ketamine Genotyping will be performed using Illumina Omni 2.5 + exome array. Biomarker identification will be performed considering the genetic contribution of variants focusing on 10 candidate genes relevant for the biotransformation (CYP2B6, CYP2C9, CYP3A4, CYP3A5, CYP2A6) and for pharmacodynamics (genes encoding for the NMDA receptor subunits: GRIN1 e GRIN2A-D) of ketamine, selected on the basis of literature. The independent variable associated with ketamine induced adverse effects will be the presence or not of functional variants in the candidate genes. 10 minutes before procedural sedation
Secondary To assess the maximum plasmatic concentration (Cmax) after intravenous administration of ketamine Ketamine and its main metabolite norketamine will be quantified in plasma through a method of liquid chromatography / tandem mass spectrometry. The pharmacokinetic parameters will be calculated using WinNonlin software. 10 minutes before procedural sedation
Secondary To assess the area under the concentration curve from time 0 (AUC 0-last) after intravenous administration of ketamine Ketamine and its main metabolite norketamine will be quantified in plasma through a method of liquid chromatography / tandem mass spectrometry. The pharmacokinetic parameters will be calculated using WinNonlin software. 10 minutes before procedural sedation
Secondary To assess the plasmatic half-life after intravenous administration of ketamine Ketamine and its main metabolite norketamine will be quantified in plasma through a method of liquid chromatography / tandem mass spectrometry. The pharmacokinetic parameters will be calculated using WinNonlin software. 10 minutes before procedural sedation
Secondary To assess the plasmatic clearance defined as dose/AUC after intravenous administration of ketamine Ketamine and its main metabolite norketamine will be quantified in plasma through a method of liquid chromatography / tandem mass spectrometry. The pharmacokinetic parameters will be calculated using WinNonlin software. 10 minutes before procedural sedation
Secondary To identify exosomal miRNAs linked to the development of emesis and recovery agitation after intravenous administration of ketamine Neuronal-derived exosomes will be isolated and miRNAs will be sequenced. miRNAs contained in neuronal-derived exosomes and associated with ketamine induced adverse effects will be quantified through next generation sequencing. 10 minutes before procedural sedation
See also
  Status Clinical Trial Phase
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Completed NCT00694174 - Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants Phase 4
Completed NCT06264960 - The Effect of Music Therapy and Breathing Exercise on Anxiety and Pain in Patients Undergoing Coronary Angiography N/A
Recruiting NCT06354608 - The Effect of Audio Book and Local Vibration on Pain and Fear in Intramuscular Injection in Children N/A
Completed NCT05073497 - Efficacy of Finger Puppet as a Distraction Method N/A
Recruiting NCT05275881 - Impact of Virtual Reality in Pediatric Hematology and Oncology N/A
Completed NCT05656677 - Parental Involvement in Pain Reducing Measures N/A
Completed NCT04257019 - Pain, Anxiety During Interventional Spine Procedures N/A
Completed NCT05166551 - Effect of Acupressure on Interventional Pain in Infants N/A
Completed NCT04421430 - Nonpharmacological Methods for Children in Procedural Pain N/A
Completed NCT06380556 - The Effect of Mechanical Vibration and ShotBlocker on Pain Levels During Heel Lance in Healthy Term Neonates N/A
Not yet recruiting NCT05555498 - Virtual Reality for Anxiety and Pain Management During Oocyte Retrieval in IVF/ICSI Treatment N/A
Completed NCT03985930 - Non-immersive Virtual Reality for Pediatric Pain Management N/A
Completed NCT05179291 - Efficacy of VR and Buzzy on Pain and Anxiety N/A
Completed NCT05070325 - Nonpharmacological Methods for Children N/A
Completed NCT00150189 - Utilization of Oral Sucrose to Decrease Pain in Infants During Immunizations N/A
Completed NCT04254081 - Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion Phase 4
Recruiting NCT05895383 - Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy Phase 4
Not yet recruiting NCT06373627 - Procedural Pain Management by Multimodal Sedation Analgesia Combining Hypnosis in Children With Congenital Heart Disease N/A
Recruiting NCT04967118 - Neonatal Pain Management and Pain Monitoring Using New Methods N/A